Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infectionmidwayadmin2020-05-15T15:04:15+00:00
Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
MK8591A-020 · Trial ·
Major Inclusion/Exclusion Criteria:
- Never been on HIV medication
- HIV RNA between 500-100,00 copies